171
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

In-silico investigations on the anticancer activity of selected 2-aryloxazoline derivatives against breast cancer

, ORCID Icon & ORCID Icon
Pages 8392-8401 | Received 06 Jul 2022, Accepted 03 Oct 2022, Published online: 16 Oct 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Peilin Pang, Senchen Liu, Xiafei Hao, Yuxin Tian, Shuyue Gong, Dongqiang Miao & Yanjun Zhang. (2023) Exploring binding modes of the selected inhibitors to SND1 by all-atom molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-15.
Read now
Abirami Arunachalam, Muthumanickam Sankar, Boomi Pandi, Soumi Paul & Sivasudha Thilagar. Evaluation of Rapanone and Nectandrin B as novel inhibitors for targeting the metastatic regulator protein BACH1 using breast cancer cell line Mcf-7. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-16.
Read now

Articles from other publishers (1)

Mahbub Alam, Mohammed Nurul Abser, Ajoy Kumer, Md Mosharef Hossain Bhuiyan, Parul Akter, Md Emdad Hossain & Unesco Chakma. (2023) Synthesis, characterization, antibacterial activity of thiosemicarbazones derivatives and their computational approaches: Quantum calculation, molecular docking, molecular dynamic, ADMET, QSAR. Heliyon 9:6, pages e16222.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.